Search results
Results from the WOW.Com Content Network
Belantamab mafodotin was evaluated in DREAMM-2 (NCT 03525678), an open-label, multicenter trial. [5] Participants received either belantamab mafodotin, 2.5 mg/kg or 3.4 mg/kg intravenously, once every three weeks until disease progression or unacceptable toxicity.
On 13 February 2007, HGS and GSK announced the initiation of the first of two Phase III clinical trials of belimumab in patients with active lupus erythematosus. [21] Two Phase III clinical studies were conducted, involving a total of 1,684 patients with scores of ≥6 on the SELENA-SLEDAI assessment of lupus activity.
Pharmaceutical maker GlaxoSmithKline will begin a phase 3 clinical trial to judge lupus medication Benlysta's effectiveness in treating patients with ANCA-positive vasculitis. The trial, which ...
A case report form (or CRF) is a paper or electronic questionnaire specifically used in clinical trial research. [1] The case report form is the tool used by the sponsor of the clinical trial to collect data from each participating patient. All data on each patient participating in a clinical trial are held and/or documented in the CRF ...
Lerdelimumab is a human monoclonal antibody to TGF beta 2, [90] initially developed to combat fibrotic scarring that results from glaucoma drainage surgery. [91] The drug was branded Trabio, and development was stopped in late 2005 after unsuccessful trial results. [92] Bertilimumab (CAT-213) is a human monoclonal antibody to eotaxin 1. [93]
Sales of Human Genome Sciences' (NAS: HGSI) new lupus drug Benylsta continues to grow -- just not fast enough to keep investors interest. The stock traded down more than 20% today after net sales ...
Benlysta: mab: human: B-cell activating factor (BAFF) Y: systemic lupus erythematosus without renal or CNS involvement Bemarituzumab [26] mab: humanized: FGFR2: gastric cancer or gastroesophageal junction adenocarcinoma Benralizumab [38] Fasenra: mab: humanized: CD125: Y: asthma Berlimatoxumab [26] mab: human: Staphylococcus aureus bi-component ...
Slow and steady might win the race, but it isn't a way to keep biotech investors' interest. As we approach a year after GlaxoSmithKline (NYS: GSK) and Human Genome Sciences' (NAS: HGSI) Benlysta ...